Overview

• The FDA's decision to reconsider follows a lawsuit by the Outsourcing Facilities Association, arguing tirzepatide remains in short supply.
• Compounded versions of tirzepatide are more affordable alternatives for patients, especially with limited insurance coverage for weight loss uses.
• Eli Lilly has been actively opposing the production of compounded versions, issuing cease-and-desist letters to various sellers.
• The FDA's initial removal of tirzepatide from the shortage list was met with significant backlash from pharmacies and patients.
• Despite the FDA's claim of resolved shortages, pharmacies report ongoing difficulties in obtaining the branded drug.